Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
New Post
Former Ontrak CEO receives 42 months in prison for insider trading in DOJ’s first Rule 10b5-1 trading plan prosecution
June 25, 2025
News Alert
Former Miami-based hedge fund manager faces insider trading charges in Massachusetts
June 18, 2025
News Alert
Connecticut executive pleads guilty to insider trading
June 10, 2025
News Alert